InnoCare Pharma Completes Patient Enrollment for Phase II Trial of ICP-488, Advancing Novel Psoriasis Treatment

InnoCare Pharma,  a leading biopharmaceutical company dedicated to revolutionizing the treatment of cancer and autoimmune diseases, proudly announces ...

May 16, 2024 | Thursday | News
Genentech Reports Positive Phase Ib Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People With Obesity

Genentech, a member of the Roche Group  announced positive results from the Phase Ib clinical trial of CT-388, a dual GLP-1/GIP receptor agonist being...

May 16, 2024 | Thursday | News
HUTCHMED Initiates Registrational Phase III Clinical Trial of HMPL-306 for Relapsed / Refractory Acute Myeloid Leukemia in China

  AML, a challenging hematological malignancy, often involves mutations of IDH1 and IDH2 enzymes, necessitating innovative treatment strategies. HMPL...

May 14, 2024 | Tuesday | News
CytomX Therapeutics Collaborates with MSD for First-in-Human Trial of Novel CX-801 Cytokine to Revolutionize Cancer Treatment

- CX-801 is a dually masked, conditionally activated IFNα2b cytokine designed using the CytomX Probody® Therapeutic Platform - - Phase 1 first-i...

May 08, 2024 | Wednesday | News
Innovent Biologics Receives Breakthrough Therapy Designation for IBI343 in Advanced Gastric Cancer Treatment

Innovent Biologics a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncol...

May 07, 2024 | Tuesday | News
High Response Rate in Marginal Zone Lymphoma Patients: Initial Data Shows ZYNLONTA® Efficacy

Initial data from 15 patients with relapsed/refractory (r/r) marginal zone lymphoma (MZL) show 13 patients achieved a complete response and one patient ach...

May 06, 2024 | Monday | News
Walgreens and Boehringer Ingelheim Forge Strategic Partnership to Democratize Clinical Trials

Walgreens and Boehringer Ingelheim announced a strategic collaboration aimed at optimizing recruitment and making clinical trials more accessible, inclusiv...

May 03, 2024 | Friday | News
Beyfortus (nirsevimab) Proves Potent Against RSV Hospitalizations in Infants

New real-world evidence shows Beyfortus (nirsevimab) substantially reduced RSV lower respiratory tract disease and hospitalizations in infants during the...

May 03, 2024 | Friday | News
HiberCell Initiates Phase 1b Trial for Combination Therapy in Advanced Kidney Cancer

HiberCell, Inc., a clinical-stage biotechnology company developing therapeutics to address cancer relapse, metastasis, and resistance, is pleased to announ...

May 02, 2024 | Thursday | News
NKGen Biotech's SNK01 NK Cell Therapy Clears FDA IND Hurdle for Parkinson’s

The Company expects to initiate a Phase 1 clinical trial in PD in 2H 2024. NKGen Biotech, Inc. , a clinical-stage biotechnology company focused on the dev...

April 30, 2024 | Tuesday | News
Abzena Introduces EpiScreen® 2.0: Transforms Immunogenicity Assessment for Advanced Therapeutics

Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, has announced the launch of its enhanced bioassay platform EpiScree...

April 29, 2024 | Monday | News
Hyundai Bioscience Announces Clinical Development Plan for Oral Niclosamide Metabolic Anticancer Drug Targeting p53 Gene Mutations

Hyundai Bioscience announced its clinical development plan of oral "Niclosamide Metabolic Anticancer Drug" targeting cancer patients with intractable cance...

April 25, 2024 | Thursday | News
Gain Therapeutics Reports Positive Results from Phase 1 Study of GT-02287, Showcasing Promising Safety and Tolerability Profile

Gain Therapeutics, a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapi...

April 25, 2024 | Thursday | News
Shanghai Junshi Biosciences' Toripalimab NDA Accepted by Hong Kong DO for Groundbreaking Nasopharyngeal Carcinoma Treatment

Shanghai Junshi Biosciences , a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel...

April 25, 2024 | Thursday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close